In-depth discussion of the efficacy and application of Platinib

Pralsetinib is a highly selective RET inhibitor, mainly used to treat a variety of malignant tumors caused by RET gene fusion or mutation, including non-small cell lung cancer (NSCLC) , medullary thyroid carcinoma (MTC) and other RET-related solid tumors. RET gene rearrangements or mutations can trigger abnormal growth of tumor cells, and platinib inhibits the RET signaling pathway and blocks the proliferation of cancer cells, thereby exerting an anti-tumor effect. This article will deeply discuss the efficacy, indications, and clinical applications of platinib, and provide a comprehensive medical reference for clinicians and patients.

1. The mechanism of action of platinib

Platinib is an oral small molecule kinase inhibitor whose main role is to target RET fusion or RET mutation-positive tumors. The tyrosine kinase encoded by the RET (Rearranged during Transfection) gene is abnormally expressed in a variety of cancers. Mutation or fusion of the RET gene can lead to continued activation of downstream signaling pathways, causing uncontrolled growth of tumor cells. Platinib reduces the proliferation of cancer cells by selectively inhibiting RET kinase activity, while inducing cell apoptosis, ultimately achieving anti-tumor effects.

Compared with traditional multi-target tyrosine kinase inhibitors (TKIs), platinib is more selective and has a stronger inhibitory effect on RET targets. Therefore, it shows better efficacy in the treatment of RET-positive tumors and has less impact on non-RET targets, reducing unnecessary side effects.

2. Indications and clinical applications of platinib

The indications of platinib mainly include the following categories:

1. RET fusion-positive non-small cell lung cancer (NSCLC): Among patients with non-small cell lung cancer, about 1%-2% have RET gene fusion. For this group of patients, platinib can be used as first-line or second-line treatment, especially for patients who have previously received platinum-containing chemotherapy but whose disease has progressed. Clinical studies have shown that platinib exhibits a high objective response rate (ORR) and durable efficacy in patients with RET-positive NSCLC.

2. RET-mutated medullary thyroid cancer (MTC): Medullary thyroid cancer (MTC) is a malignant tumor derived from thyroid C cells. About 60% of hereditary MTC and 10%-20% of sporadic MTC patients have RET gene mutations. For this group of patients, platinib can be used as a first- or second-line treatment, especially for patients who have previously received radioactive iodine therapy or other systemic treatments that are ineffective.

3. Analysis of clinical efficacy of platinib

The efficacy of platinib has been verified in multiple clinical trials, the most representative of which is theARROW clinical trial. In patients with RET fusion-positive NSCLC, the overall response rate (ORR) of first-line treatment is as high as 70%, with a complete response (CR) rate of 5%-10%. For patients who have previously received platinum-containing chemotherapy, the ORR can still reach 57%-61%, showing a good and durable anti-tumor effect. In patients with RET-mutated MTC, the ORR is 60%-70%, and some patients have a significant reduction in tumor burden and a disease control rate (DCR) close to 90%.

Reference: https://gavreto.com/